Pfizer

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

Appeals court turns Enhertu patent dispute on its head

A US appeals court has reversed a 2023 decision that ordered Daiichi Sankyo to pay royalties on sales of cancer drug Enhertu to Seagen (now Pfizer).

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

As year-end nears, pharma groups plump up their pipelines

Padcev/Keytruda scores again in early bladder cancer

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's $2bn+ obesity bet, and other weight-loss news

Appeals court turns Enhertu patent dispute on its head

EMA starts review of 'transformative' bladder cancer therapy

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks